| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5811423 | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Aug, 2012
(11 years ago) | |
| US5519021 | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
May, 2013
(10 years ago) | |
|
US5519021 (Pediatric) | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Nov, 2013
(10 years ago) | |
| US5663169 | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Sep, 2014
(9 years ago) | |
|
US5663169 (Pediatric) | BRISTOL MYERS SQUIBB | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Mar, 2015
(9 years ago) | |
| US6939964 | BRISTOL MYERS SQUIBB | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jan, 2018
(6 years ago) | |
| US6639071 | BRISTOL MYERS SQUIBB | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Feb, 2018
(6 years ago) | |
|
US6939964 (Pediatric) | BRISTOL MYERS SQUIBB | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jul, 2018
(5 years ago) | |
|
US6639071 (Pediatric) | BRISTOL MYERS SQUIBB | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Aug, 2018
(5 years ago) | |
| US6238695 | BRISTOL MYERS SQUIBB | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Apr, 2019
(5 years ago) | |
| US6555133 | BRISTOL MYERS SQUIBB | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Apr, 2019
(5 years ago) | |
|
US6555133 (Pediatric) | BRISTOL MYERS SQUIBB | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Oct, 2019
(4 years ago) | |
|
US6238695 (Pediatric) | BRISTOL MYERS SQUIBB | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
Oct, 2019
(4 years ago) | |
Sustiva is owned by Bristol Myers Squibb.
Sustiva contains Efavirenz.
Sustiva has a total of 13 drug patents out of which 13 drug patents have expired.
Expired drug patents of Sustiva are:
- US5811423
- US5519021
- US5519021*PED
- US5663169
- US5663169*PED
- US6939964
- US6639071
- US6939964*PED
- US6639071*PED
- US6238695
- US6555133
- US6555133*PED
- US6238695*PED
Sustiva was authorised for market use on 17 September, 1998.
Sustiva is available in tablet;oral, capsule;oral dosage forms.
Sustiva can be used as treatment of hiv infection in combination with one or more additional hiv antiviral agents, treatment of hiv, treatment of hiv infection.
The generics of Sustiva are possible to be released after 06 October, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 02, 2016 |
| Pediatric Exclusivity(PED) | Nov 02, 2016 |
Drugs and Companies using EFAVIRENZ ingredient
Market Authorisation Date: 17 September, 1998
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents; Treatment of hiv infection; Treatment of hiv
Dosage: CAPSULE;ORAL; TABLET;ORAL
SUSTIVA family patents
